TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

Currently, the study of mechanisms of development and introduction of the most effective treatment for castration-resistant prostate cancer (CRPC) – one of the most highlighted problems concerning facing oncologists and urologists worldwide. Several large randomized trials recently (TAX 327 , SWOG 9...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. N. Skvortsova, S. V. Mishugin, A. A. Gritskevich, I. G. Rusakov
Format:	Article
Language:	English
Published:	Bashkir State Medical University 2017-01-01
Series:	Креативная хирургия и онкология
Subjects:	castration-resistant cancer prostate docetaxel cabazitaxel taxanes
Online Access:	https://www.surgonco.ru/jour/article/view/12
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Activation of PI3K/AKT/mTOR Signaling Pathway in Response to Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer Cells
by: Işıl Ezgi Eryılmaz, et al.
Published: (2021-12-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

The efficacy and safety of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis based on randomized controlled trials
by: Cong Shao, et al.
Published: (2025-07-01)

Taxanes – The backbone of medical oncology
by: Wesley M Jose
Published: (2020-01-01)

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis
by: Azka Syed, et al.
Published: (2025-07-01)

Role of exosomes in castration-resistant prostate cancer
by: Yuan Cao, et al.
Published: (2025-05-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

Screening and validation of key genes involved in castration-resistant prostate cancer based on transcriptomics sequencing
by: Guangquan Tong, et al.
Published: (2025-07-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study
by: Kambiz Rahbar, et al.
Published: (2025-07-01)

Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer
by: Haq Dad, et al.
Published: (2025-01-01)

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)

Enhancing in Vitro anti-metastatic efficacy and deep penetration into tumor spheroid of docetaxel-loaded liposomes via size optimization for prostate cancer treatment
by: Saksorn Klibaim, et al.
Published: (2025-03-01)

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
by: Sandra Doveson, et al.
Published: (2025-03-01)

Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer
by: Yuqi Guo, et al.
Published: (2025-03-01)

A novel lncRNA FLJ promotes castration resistance in prostate cancer through AR mediated autophagy
by: Yingying Wu, et al.
Published: (2025-03-01)

Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting
by: Jayachandran Perumal Kalaiyarasi, et al.
Published: (2019-01-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
by: Sabin Göktaş Aydın, et al.
Published: (2023-03-01)

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review
by: Zineddine Belabaci, et al.
Published: (2025-05-01)

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
by: Alexander W Wyatt, et al.
Published: (2015-04-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)

Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01)

Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center
by: Thomas Büttner, et al.
Published: (2024-12-01)

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
by: Hejar Atalan, et al.
Published: (2025-06-01)

Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01)

Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005–2024)
by: Jiexiang Zhang, et al.
Published: (2025-07-01)

Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
by: Fangming Wang, et al.
Published: (2025-05-01)

MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration—Where Are We Now?
by: Mariana Ferreira, et al.
Published: (2024-10-01)

Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
by: G. George, et al.
Published: (2025-03-01)

Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer (CRPC) Patients: CaPA Study
by: Pedro Costa, et al.
Published: (2025-08-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer
by: Maria Malvina Tsamouri, et al.
Published: (2025-08-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis
by: Nader Al Nakouzi, et al.
Published: (2016-05-01)